



CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Join us for this interactive, live stream webinar featuring expert perspectives on new targeted therapies to treat patients with HR+/HER2- EBC, including a review of current and emerging published data and how to individualize the selection of systemic therapy for appropriate patients.

ESMO Breast Virtual Webcast
5 May 2021 | 19.00 CEST

FACULTY PRESENTERS

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen R.D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine & Head of Medical Oncology,
Consultant Medical Oncologist & Head of The Breast Unit,
The Royal Marsden NHS Foundation Trust &
The Institute of Cancer Research,
Fulham Road, Chelsea, London, United Kingdom

Sara Tolaney, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

AGENDA

- Medical Need to Improve on Standard Therapies for HR+/HER2- EBC
- Individualizing Therapeutic Decision-Making for Patients With HR+/HER2- EBC
- Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence
- Debating Optimal Neoadjuvant Therapy
- Future Considerations on the Horizon for HR+/HER2- EBC
- Summary, Final Thoughts, and Question and Answer Session

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Provided by Clinical Care Options, LLC.



CLINICAL CARE OPTIONS®
ONCOLOGY